These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25156857)

  • 1. Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel.
    Deharo P; Pankert M; Bonnet G; Quilici J; Bassez C; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Int J Cardiol; 2014 Oct; 176(3):1200-2. PubMed ID: 25156857
    [No Abstract]   [Full Text] [Related]  

  • 2. Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests.
    Dillinger JG; Manzo Silberman S; Bal dit Sollier C; Amsallem M; Sideris G; Voicu S; Henry P; Drouet L
    Int J Cardiol; 2014 Sep; 176(2):557-9. PubMed ID: 25074556
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
    Bernlochner I; Goedel A; Plischke C; Schüpke S; Haller B; Schulz C; Mayer K; Morath T; Braun S; Schunkert H; Siess W; Kastrati A; Laugwitz KL
    Eur Heart J; 2015 Dec; 36(45):3202-10. PubMed ID: 26216931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
    Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
    Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
    Alexopoulos D; Xanthopoulou I; Davlouros P; Tsigkas G; Damelou A; Theodoropoulos KC; Gkizas V; Hahalis G
    J Thromb Haemost; 2013 Feb; 11(2):381-4. PubMed ID: 23216658
    [No Abstract]   [Full Text] [Related]  

  • 8. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
    Coleman CI; Limone BL
    Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
    Lhermusier T; Voisin S; Murat G; Mejean S; Garcia C; Bataille V; Lipinski MJ; Carrié D; Sié P
    Int J Cardiol; 2014 Jul; 174(3):874-6. PubMed ID: 24820749
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome.
    Cuisset T; Cayla G; Quilici J; Pankert M; Deharo P; Bonnet G; Grosdidier C; Beguin S; Morange P; Bonnet JL; Alessi MC
    Int J Cardiol; 2013 Oct; 168(3):2988-9. PubMed ID: 23642612
    [No Abstract]   [Full Text] [Related]  

  • 11. Development and clinical use of prasugrel and ticagrelor.
    Ahmad S; Storey RF
    Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era for antiplatelet therapy in patients with acute coronary syndrome.
    Dib C; Hanna EB; Abu-Fadel MS
    Am J Med Sci; 2010 Nov; 340(5):407-11. PubMed ID: 20818228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
    Laine M; Frère C; Toesca R; Berbis J; Barnay P; Pansieri M; Michelet P; Bessereau J; Camilleri E; Ronsin O; Helal O; Paganelli F; Dignat-George F; Bonello L
    Thromb Haemost; 2014 Feb; 111(2):273-8. PubMed ID: 24154787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome.
    Bassez C; Deharo P; Pankert M; Bonnet G; Quilici J; Lambert M; Verdier V; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Int J Cardiol; 2014 Oct; 176(3):1184-5. PubMed ID: 25129298
    [No Abstract]   [Full Text] [Related]  

  • 16. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice.
    Sibbing D; Orban M; Massberg S
    Hamostaseologie; 2013; 33(1):9-15. PubMed ID: 23299202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
    Piccolo R; Di Gioia G; Niglio T; D'Anna C; De Rosa R; Strisciuglio T; Bevilacqua M; Piscione F; Cirillo P; Galasso G
    Angiology; 2014 Feb; 65(2):130-6. PubMed ID: 23221279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
    Torngren K; Ohman J; Salmi H; Larsson J; Erlinge D
    Cardiology; 2013; 124(4):252-8. PubMed ID: 23594617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.